CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment

Estrogen catabolism is a major function of CYP2C19. The effect of CYP2C19 polymorphisms on tamoxifen sensitivity may therefore not only be mediated by a variation in tamoxifen metabolite levels but also by an effect on breast cancer risk and molecular subtype due to variation in lifelong exposure to...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Beelen, K., Opdam, M., Severson, T. M., Koornstra, R. H. T., Vincent, A. D., Hauptmann, M., van Schaik, R. H. N., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., Linn, S. C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2013
Aiheet:
Preclinical Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3695326/
https://ncbi.nlm.nih.gov/pubmed/23736997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2568-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia